The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
Open accessAbstract
One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs.We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs.Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs.Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice.Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19.We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.Nonstandard abbreviations used: indoleamine 2,3-dioxygenase (IDO); 1-methyl-D-tryptophan (1MT); mixed leukocyte reaction (MLR); plasmacytoid DC (pDC); regulatory T cell (Treg); T cell receptor (TCR); tumor-draining LN (TDLN). Conflict of interest:The authors have declared that no conflict of interest exists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, heightened activity of the Trp-Kyn-AhR pathway has been linked to impairment of antitumor immunity and tumor growth (16,17).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,162
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I. E., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,640
Self-citationModulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,204
Commitment to the B-lymphoid lineage depends on the transcription factor Pax5
Nutt, S. L., Heavey, B., Rolink, A. G., & Busslinger, M. (1999) · Nature · doi:10.1038/44076 · Cited by 1,179
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y.-C., Golumbek, P. T., Ahmadzadeh, M., Jaffee, E. M., Pardoll, D. M., & Levitsky, H. I. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,159
Research works printed but not linked: 2
- Cuenca, 2003, Cancer Res., 63, 9007
- Almand, 2000, Clin. Cancer Res., 6, 1755
Cited by
Sorted by citations
Items 101–200 of 877
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?
Üstün, C., Miller, J. S., Munn, D. H., Weisdorf, D. J., & Blazar, B. R. (2011) · Blood · doi:10.1182/blood-2011-07-365817 · Cited by 222
Self-citationInaba, T., Ino, K., Kajiyama, H., Yamamoto, E., Shibata, K., Nawa, A., Nagasaka, T., Akimoto, H., Takikawa, O., & Kikkawa, F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.07.015 · Cited by 220
Bishnupuri, K. S., Alvarado, D. M., Khouri, A. N., Shabsovich, M., Chen, B., Dieckgraefe, B. K., & Ciorba, M. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0668 · Cited by 215
Metabolic Control of Dendritic Cell Functions: Digesting Information
Wculek, S. K., Khouili, S. C., Priego, E., Heras‐Murillo, I., & Sancho, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00775 · Cited by 218
Wang, X., Wang, H., Wang, H., Zhang, F., Wang, K.-F., Guo, Q., Zhang, G., Cai, S., & Du, J. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.02.005 · Cited by 214
IDO Expression in Cancer: Different Compartment, Different Functionality?
Meireson, A., Devos, M., & Brochez, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.531491 · Cited by 215
Ladomersky, E., Zhai, L., Lenzen, A. C., Lauing, K. L., Qian, J., Scholtens, D. M., Gritsina, G., Sun, X., Liu, Y., Yu, F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3573 · Cited by 208
Immunogenicity of Adult Mesenchymal Stem Cells: Lessons from the Fetal Allograft
Barry, F., Murphy, M. J., English, K., & Mahon, B. P. (2005) · Stem Cells and Development · doi:10.1089/scd.2005.14.252 · Cited by 200
Targeting amino acid metabolism in cancer growth and anti-tumor immune response
Ananieva, E. A. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.281 · Cited by 203
Prendergast, G. C., Mondal, A., Dey, S., Laury‐Kleintop, L. D., & Muller, A. J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.11.005 · Cited by 200
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity
McGaha, T. L., Huang, L., Lemos, H. D. P., Metz, R. A., Mautino, M. R., Prendergast, G. C., & Mellor, A. L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01149.x · Cited by 202
Self-citationMatta, B. M., Castellaneta, A., & Thomson, A. W. (2010) · European Journal of Immunology · doi:10.1002/eji.201040839 · Cited by 201
Jegalian, A. G., Facchetti, F., & Jaffe, E. S. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181bb6bc2 · Cited by 192
Trial watch: IDO inhibitors in cancer therapy
Naour, J. L., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 195
Yang, S., Li, X., Hu, F., Li, Y., Yang, Y., Yan, J., Kuang, C., & Yang, Q. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401195n · Cited by 187
Toward the identification of a tolerogenic signature in IDO-competent dendritic cells
Orabona, C., Puccetti, P., Vacca, C., Bicciato, S., Luchini, A., Fallarino, F., Bianchi, R., Velardi, E., Perruccio, K., Velardi, A., et al. (2005) · Blood · doi:10.1182/blood-2005-10-4077 · Cited by 188
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 192
Soliman, H. H., Mediavilla-Varela, M., & Antonia, S. J. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3343 · Cited by 182
Self-citationTryptophan-Catabolizing Enzymes – Party of Three
Ball, H. J., Jusof, F. F., Bakmiwewa, S. M., Hunt, N. H., & Yuasa, H. J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00485 · Cited by 186
Sharma, M. D., Huang, L., Choi, J.-H., Lee, E.-J., Wilson, J. M., Lemos, H. D. P., Pan, F., Blazar, B. R., Pardoll, D. M., Mellor, A. L., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.01.013 · Cited by 180
Self-citationAmador-Molina, A., Hernández-Valencia, J., Lamoyi, E., Contreras‐Paredes, A., & Lizano, M. (2013) · Viruses · doi:10.3390/v5112624 · Cited by 180
Belladonna, M. L., Grohmann, U., Guidetti, P., Volpi, C., Bianchi, R., Fioretti, M. C., Schwarcz, R. M., Fallarino, F., & Puccetti, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.130 · Cited by 184
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179
Holtzhausen, A., Zhao, F. L., Evans, K. S., Tsutsui, M., Orabona, C., Tyler, D. S., & Hanks, B. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0167 · Cited by 179
Indoleamine 2,3-Dioxygenase and Dendritic Cell Tolerogenicity
Harden, J. L., & Egilmez, N. K. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.676122 · Cited by 177
Baban, B., Hansen, A. M., Chandler, P., Manlapat, A., Bingaman, A. W., Kahler, D. J., Munn, D. H., & Mellor, A. L. (2005) · International Immunology · doi:10.1093/intimm/dxh271 · Cited by 177
Self-citationKrause, D., Suh, H.-S., Tarassishin, L., Cui, Q., Durafourt, B. A., Choi, N., Bauman, A., Cosenza-Nashat, M. A., Antel, J. P., Zhao, M., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.05.048 · Cited by 178
Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation
Munn, D. H. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.002 · Cited by 177
Self-citationBanerjee, T., DuHadaway, J. B., Gaspari, P. M., Sutanto‐Ward, E., Munn, D. H., Mellor, A. L., Malachowski, W. P., Prendergast, G. C., & Muller, A. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210939 · Cited by 176
Self-citationSharma, M. D., Hou, D., Baban, B., Koni, P. A., He, Y., Chandler, P., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2010) · Immunity · doi:10.1016/j.immuni.2010.11.022 · Cited by 174
Self-citationSaxena, V., Ondr, J. K., Magnusen, A. F., Munn, D. H., & Katz, J. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5041 · Cited by 178
Self-citationBianco, N. R., Kim, S. H., Ruffner, M. A., & Robbins, P. D. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24229 · Cited by 176
Routy, J., Routy, B., Graziani, G. M., & Mehraj, V. (2016) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s38355 · Cited by 171
Romani, L. R., Bistoni, F., Perruccio, K., Montagnoli, C., Gaziano, R., Bozza, S., Bonifazi, P., Bistoni, G., Rasi, G., Velardi, A., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004762 · Cited by 171
Kumar, S., Malachowski, W. P., DuHadaway, J. B., LaLonde, J. M., Carroll, P. J., Jaller, D., Metz, R. A., Prendergast, G. C., & Muller, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7014155 · Cited by 171
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
Pan, K., Wang, H., Chen, M.-S., Zhang, H.-K., Weng, D., Zhou, J., Huang, W. C., Li, X. H., Song, H.-F., & Xia, J. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0395-1 · Cited by 173
Dendritic cells in the tumor microenvironment: prognostic and theranostic impact
Verneau, J., Sautès‐Fridman, C., & Sun, C. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101410 · Cited by 171
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Löb, S., Königsrainer, A., Schäfer, R., Rammensee, H., Opelz, G., & Terness, P. (2007) · Blood · doi:10.1182/blood-2007-10-116111 · Cited by 167
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
Perng, P., & Lim, M. K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00153 · Cited by 171
Nakamura, T., Shima, T., Saeki, A., 日高, 隆., Nakashima, A., Takikawa, O., & Saito, S. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00470.x · Cited by 169
Dendritic Cells and Tumor Microenvironment: A Dangerous Liaison
Fricke, I., & Gabrilovich, D. I. (2006) · Immunological Investigations · doi:10.1080/08820130600803429 · Cited by 172
Plebanek, M. P., Xue, Y., Nguyen, Y.-V., DeVito, N. C., Wang, X., Holtzhausen, A., Beasley, G. M., Theivanthiran, B., & Hanks, B. A. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi4191 · Cited by 164
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M. M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 166
Shurin, M. R., Shurin, G. V., Lokshin, A. E., Yurkovetsky, Z. R., Gutkin, D. W., Chatta, G. S., Zhong, H., Han, B., & Ferris, R. L. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9010-6 · Cited by 166
Ribas, A., Hanson, D. C., Noe, D. A., Millham, R., Guyot, D. J., Bernstein, S. H., Canniff, P. C., Sharma, A., & Gómez-Navarro, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-873 · Cited by 162
IDO1: An important immunotherapy target in cancer treatment
Li, F., Zhang, R., Li, S., & Liu, J. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.024 · Cited by 162
Immune suppression and reversal of the suppressive tumor microenvironment
Shimizu, K., Iyoda, T., Okada, M., Yamasaki, S., & Fujii, S. (2018) · International Immunology · doi:10.1093/intimm/dxy042 · Cited by 162
Hill, M., Pereira, V., Chauveau, C., Zagani, R., Remy, S., Tesson, L., Mazal, D., Ubillos, L., Brion, R., Ashgar, K., et al. (2005) · The FASEB Journal · doi:10.1096/fj.05-3875com · Cited by 158
Potula, R., Poluektova, L. Y., Knipe, B., Chrastil, J., Heilman, D., Dou, H., Takikawa, O., Munn, D. H., Gendelman, H. E., & Persidsky, Y. (2005) · Blood · doi:10.1182/blood-2005-04-1403 · Cited by 159
Self-citationDirecting Dendritic Cell Immunotherapy Towards Successful Cancer Treatment
Sabado, R. L., & Bhardwaj, N. (2009) · Immunotherapy · doi:10.2217/imt.09.43 · Cited by 155
Therapeutic induction of antigen-specific immune tolerance
Kenison, J. E., Stevens, N. A., & Quintana, F. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00970-x · Cited by 162
IDO expression in the brain: a double-edged sword
Kwidzinski, E., & Bechmann, I. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0229-7 · Cited by 154
Improving cancer immunotherapy by targeting tumor-induced immune suppression
Stewart, T. J., & Smyth, M. J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9280-5 · Cited by 152
Dias, J. D., Hemminki, O., Diaconu, I., Hirvinen, M., Bonetti, A., Guse, K., Escutenaire, S., Kanerva, A., Pesonen, S. K., Loskog, A., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.176 · Cited by 149
Indoleamine 2,3 dioxygenase and regulation of T cell immunity
Mellor, A. L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.232 · Cited by 149
Self-citationQian, F., Villella, J., Wallace, P. K., Mhawech-Fauceglia, P. Y., Tario, J. D., Andrews, C., Matsuzaki, J., Valmori, D., Ayyoub, M., Frederick, P. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2106 · Cited by 148
Bailey-Bucktrout, S. L., Caulkins, S. C., Goings, G. E., Fischer, J. A. A., Dzionek, A., & Miller, S. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6457 · Cited by 156
Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Muller, A. J., & Prendergast, G. C. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780006896 · Cited by 147
A phase I study of indoximod in patients with advanced malignancies
Soliman, H. H., Minton, S. E., Han, H. S., Ismail-Khan, R. R., Neuger, A. M., Khambati, F. A., Noyes, D. R., Lush, R. M., Chiappori, A., Roberts, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8216 · Cited by 145
Self-citationDysfunction of antigen processing and presentation by dendritic cells in cancer
Bandola-Simon, J. M., & Roche, P. A. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.03.025 · Cited by 142
Jochéms, C., Fantini, M. C., Fernando, R. I., Kwilas, A. R., Donahue, R. N., Lepone, L. M., Grenga, I., Kim, Y., Brechbiel, M. W., Gulley, J. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9326 · Cited by 139
Tumor associated regulatory dendritic cells
Ma, Y., Shurin, G. V., Gutkin, D. W., & Shurin, M. R. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.010 · Cited by 138
Blocking IDO activity to enhance anti-tumor immunity
Munn, D. H. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e414 · Cited by 136
Self-citationEmerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 137
Anti-HER2 vaccines: new prospects for breast cancer therapy
Ladjemi, M. Z., Jacot, W., Chardès, T., Pèlegrin, A., & Navarro‐Teulon, I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0869-2 · Cited by 134
Recent Advances in Dendritic Cell Biology
Adams, S., O’Neill, D. W., & Bhardwaj, N. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-2814-2 · Cited by 134
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
RetractedClinical Development of the Anti–CTLA-4 Antibody Tremelimumab
Ribas, A. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.010 · Cited by 134
iRGD Modified Chemo‐immunotherapeutic Nanoparticles for Enhanced Immunotherapy against Glioblastoma
Kuang, J., Song, W. L., Yin, J., Zeng, X., Han, S. H., Zhao, Y., Tao, J., Liu, C., He, X., & Zhang, X. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201800025 · Cited by 132
Ribas, A., Comı́n-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0783 · Cited by 132
Harnessing the immune system to treat cancer
Bhardwaj, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32136 · Cited by 133
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
Peyraud, F., Guégan, J., Bodet, D., Cousin, S., Bessede, A., & Italiano, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807271 · Cited by 137
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
Wainwright, D. A., Dey, M., Chang, A. L., & Lesniak, M. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00116 · Cited by 134
Criado, G., Šimelyte, E., Inglis, J. J., Essex, D. W., & Williams, R. O. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24446 · Cited by 127
Kynurenine emerges from the shadows – Current knowledge on its fate and function
Marszałek‐Grabska, M., Walczak, K., Gaweł, K., Wicha-Komsta, K., Wnorowska, S., Wnorowski, A., & Turski, W. A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107845 · Cited by 128
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Sørensen, R. B., Hadrup, S. R., Svane, I. M., Hjortsø, M. C., Straten, P. T., & Andersen, M. H. (2010) · Blood · doi:10.1182/blood-2010-06-288498 · Cited by 126
Zhang, H., Gregorio, J. D., Iwahori, T., Zhang, X., Choi, O., Tolentino, L. L., Prestwood, T. R., Carmi, Y., & Engleman, E. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610630114 · Cited by 125
Julia, R., Cornelia, H.-H., Seagal, J., Müller, W., Hermann, A. C., Rajewsky, K., & Zimber‐Strobl, U. (2007) · Blood · doi:10.1182/blood-2007-10-117655 · Cited by 125
Jasperson, L. K., Bucher, C. M., Panoskaltsis‐Mortari, A., Mellor, A. L., Munn, D. H., & Blazar, B. R. (2009) · Blood · doi:10.1182/blood-2009-06-227587 · Cited by 127
Self-citationKarunakaran, S. K., Umapathy, N. S., Thangaraju, M., Hatanaka, T., Itagaki, S., Munn, D. H., Prasad, P. D., & Ganapathy, V. (2008) · Biochemical Journal · doi:10.1042/bj20080622 · Cited by 123
Self-citationBoasso, A., Hardy, A. W., Anderson, S. A., Dolan, M. J., & Shearer, G. M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002961 · Cited by 123
Yuan, H., Manoharan, I., Suryawanshi, A. S., Majumdar, T., Angus-Hill, M. L., Koni, P. A., Manicassamy, B., Mellor, A. L., Munn, D. H., & Manicassamy, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2377 · Cited by 123
Self-citationType III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment
Hanks, B. A., Holtzhausen, A., Evans, K. S., Jamieson, R., Gimpel, P., Campbell, O. M., Hector-Greene, M., Sun, L., Tewari, A. K., George, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65745 · Cited by 123
Tumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity
Hargadon, K. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00192 · Cited by 130
Chen, B., Alvarado, D. M., Iticovici, M. S., Kau, N. S., Park, H., Parikh, P. J., Thotala, D. K., & Ciorba, M. A. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0282 · Cited by 119
Targeted Therapies to Improve Tumor Immunotherapy
Begley, J. L., & Ribas, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4804 · Cited by 118
Immune evasion in acute myeloid leukemia: current concepts and future directions
Teague, R. M., & Kline, J. P. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-13 · Cited by 119
Natural killer–dendritic cell cross-talk in cancer immunotherapy
Kaliński, P., Mailliard, R. B., Giermasz, A. S., Zeh, H. J., Basse, P. H., Bartlett, D. L., Kirkwood, J. M., Lotze, M. T., & Herberman, R. B. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.10.1303 · Cited by 117
Marrying Immunotherapy with Chemotherapy: Why Say IDO?
Muller, A. J., & Prendergast, G. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2213 · Cited by 115
The Role of Placental Tryptophan Catabolism
Sedlmayr, P., Blaschitz, A., & Stocker, R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00230 · Cited by 116
Blocking IDO activity to enhance anti-tumor immunity
David, H. M. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/414 · Cited by 114
Muller, A. J., Malachowski, W. P., & Prendergast, G. C. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.831 · Cited by 115
Opposing Biological Functions of Tryptophan Catabolizing Enzymes During Intracellular Infection
Divanovic, S., Sawtell, N. M., Trompette, A., Warning, J. I., Dias, A., Cooper, A. M., Yap, G. S., Arditi, M., Shimada, K., DuHadaway, J. B., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir621 · Cited by 116
Self-citationTumor immune escape mediated by indoleamine 2,3-dioxygenase
Ζαμανάκου, Μ., Germenis, A. E., & Karanikas, V. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.06.001 · Cited by 118
Ku, A. W., Muhitch, J. B., Powers, C. A., Diehl, M. R., Kim, M., Fisher, D. T., Sharda, A. P., Clements, V. K., O’Loughlin, K. L., Minderman, H., et al. (2016) · eLife · doi:10.7554/elife.17375 · Cited by 115
Interleukin‐10 in viral diseases and cancer: exiting the labyrinth?
Vicari, A. P., & Trinchieri, G. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00216.x · Cited by 111
Dendritic Cells, Indoleamine 2,3 Dioxygenase and Acquired Immune Privilege
Huang, L., Baban, B., Johnson, B. A., & Mellor, A. L. (2010) · International Reviews of Immunology · doi:10.3109/08830180903349669 · Cited by 111
Self-citationHuang, H., Jiang, C., Shen, S., Liu, A., Gan, Y.-J., Tong, Q., Chen, S.-B., Gao, Z., Du, J., Cao, J., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01807 · Cited by 112
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
Bilir, C., & Sarısözen, C. (2017) · Journal of Oncological Sciences · doi:10.1016/j.jons.2017.04.001 · Cited by 111
Mansfield, A. S., Heikkilä, P., Vaara, A. T., von Smitten, K., Vakkila, J., & Leidenius, M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-231 · Cited by 108
Metadata
- Authors
- Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L.
- Affiliations
- Augusta University (US)
- University of South Florida (US)
- Corresponding author
- Munn, David H.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-07-15
- Volume
- 114
- Issue
- 2
- Pages
- 280-290
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2143565660
- Cited by
- 852
- References
- 85
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 24 · 2023: 15 · 2022: 32 · 2021: 37 · 2020: 34 · 2019: 29 · 2018: 31 · 2017: 40 · 2016: 27 · 2015: 45 · 2014: 38 · 2013: 53 · 2012: 39
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Carlos and Marguerite Mason Trust
- National Institutes of Health
- National Cancer Institute (R01CA096651, R01 CA103220)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD041187)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- indoleamine 2,3-dioxygenase, plasmacytoid dendritic cells, tumor-draining lymph nodes, immunosuppression, T cell anergy, tumor antigen presentation, CD19, 1-methyl-D-tryptophan, antitumor immunity, regulatory T cells, mixed lymphocyte reaction
- MeSH terms
- Animals, Antigen-Presenting Cells, Dendritic Cells, Female, Humans, Immunosuppression Therapy, Lymph Nodes, Lymphocyte Activation, Mice, Inbred Strains, Neoplasms, Random Allocation, T-Lymphocytes, Tryptophan Oxygenase, Survival Rate, Mice, Knockout, Antigens, CD19, Adoptive Transfer, CD11c Antigen, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
